4TEEN4 Pharmaceuticals

Series-B+
4teen4.de Biotech & Healthcare
Total Funding $7.3M
Latest Round Undisclosed Series-B+
Last Announced Nov 13, 2025
Investors Undisclosed
Decision Makers 6 Verified

About 4TEEN4 Pharmaceuticals

Cardiogenic Shock: the primary circulatory shock in ICUs with a mortality rate over 70%. Triggered by acute myocardial injuries like heart attacks, it leads to severe left-ventricular dysfunction. Despite advancements in care and treatment for up to 200,000 affected U.S.

Sectors & Market Categories

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-B+
Global Headquarters Undisclosed
Tracked Since Oct 1, 2026

Web & Domain Identity

Official Website 4teen4.de
Domain Registered Date Aug 22, 2019

Social & Network Presence

X / Twitter Profile @4teen4G (29 followers) Created on Apr 2021
LinkedIn Corporate Not linked

Company Milestones & Timeline

4 Events
  1. Capital Raise

    Series-B+ announced

    fundraisingfox.com

  2. Milestone

    X account created (@4teen4G)

    29 followers

  3. Milestone

    Website domain registered

    4teen4.de

  4. Capital Raise

    Raised $7,280,000 · Series-A

    startupintros.com

Investors & Backers

Investor firms and individual backers were not publicly disclosed in available round filings for 4TEEN4 Pharmaceuticals.

Funding History

2 Rounds
Series-B+ · Nov 13, 2025
Series-A · Jan 1, 2017

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

START FREE WITH 50 CREDITS
Recently funded startups
New SaaS launches
Never pay twice for contacts